Familial Nasopharyngeal Carcinoma 6

Drug Therapy for Nasopharyngeal Carcinoma: Cytotoxic and Targeted Therapy 159in Chinese patients with metastatic nasopharyngeal carcinoma.Cancer Chemother Pharmacol 62:539–544Lo KW, Cheung ST, Leung SF, et al (1996) Hypermethylation ofthe p16 gene in nasopharyngeal carcinoma. Cancer Res56:2721–2725Lo KW, Huang DP (2002) Genetic and epigenetic changes innasopharyngeal carcinoma. Semin Cancer Biol 12:451–462Lo KW, Huang DP, Lau KM (1995) p16 gene alterations innasopharyngeal carcinoma. Cancer Res 55:2039–2043Lo KW, Kwong J, Hui AB, et al (2001) High frequency of promoterhypermethylation of RASSF1A in nasopharyngealcarcinoma. Cancer Res 61:3877–3881Louvet C, Labianca R, Hammel P, et al (2005) Gemcitabine incombination with oxaliplatin compared with gemcitabinealone in locally advanced or metastatic pancreatic cancer:results of a GERCOR and GISCAD phase III trial. J ClinOncol 23:3509–3516Low WK, Toh ST, Wee J, et al (2006) Sensorineural hearing lossafter radiotherapy and chemoradiotherapy: a single,blinded, randomized study. J Clin Oncol 24:1904–1909Ma BB, Hui EP, Chan AT (2008) Systemic approach to improvingtreatment outcome in nasopharyngeal carcinoma: currentand future directions. Cancer Sci 99:1311–1318Ma BB, Hui EP, Wong SCC, et al (2009) Multicenter phase IIstudy of gemcitabine and oxaliplatin in advanced nasopharyngealcarcinoma – correlation with excision repair crosscomplementing-1 polymorphisms Ann Oncol. *Ma B, Hui EP, King A, et al (2007) A phase II study of gefitinibin patients with metastatic or locoregionally recurrentnasopharyngeal carcinoma and evaluation of plasmaEpstein–Barr virus DNA as a biomarker of efficacy. CancerChemother Pharmacol 62:59–64Ma B, Poon T, KF To, et al (2003) Expression and prognostic significanceof epidermal growth factor receptor and HER2 proteinin nasopharyngeal carcinoma. Head Neck 2003; 25:864–872Ma J, Mai HQ, Hong MH, et al (1998) Results of a prospectiverandomized trial comparing neoadjuvant chemotherapyplus radiotherapy with radiotherapy alone in patients withlocoregionally advanced nasopharyngeal carcinoma. J ClinOncol 19:1350–1357McCarthy J, Tannock I, Degendorfer P, et al (2002) A Phase IItrial of docetaxel and cisplatin in patients with recurrent ormetastatic nasopharyngeal carcinoma. Oral Oncol 38:686Molinari R (1978) European Organization for Research onTreatment of Cancer (E.O.R.T.C.). Controlled trials of chemotherapyas an adjuvant or palliative treatment ofnasopharyngeal carcinoma. IARC Sci Publ 20:565–574Ngan RK, Yiu HH, Lau WH, et al (2002) Combination gemcitabineand cisplatin chemotherapy for metastatic or recurrentnasopharyngeal carcinoma: report of a phase II study.Ann Oncol 13:1252–1258Or YY, Hui AB, To KF, et al (2006) PIK3CA mutations innasopharyngeal carcinoma. Int J Cancer 118:1065–1067Parliament M, Jha N, Rapp E, et al (2001) Concurrent weeklycarboplatin and radiotherapy for nasopharyngealcarcinoma: report of a joint phase II study. Radiother Oncol58:131–136sPoon D, Chowbay B, Cheung YB, et al (2005) Phase II study ofirinotecan (CPT-11) as salvage therapy for advancednasopharyngeal carcinoma. Cancer 103:576–581Raymond E, Faivre S, Woynarowski JM, et al (1999) Oxaliplatin:mechanism of action and antineoplastic activity. SeminOncol 25:4–12Rossi A, Molinari R, Boracchi P, et al (1988) Adjuvant chemotherapywith vincristine, cyclophosphamide, and doxorubicinafter radiotherapy in local-regional nasopharyngealcancer: results of a 4-year multicenter randomized study. JClin Oncol 6:1401–1410Roussy InstituteGustave (1996) Preliminary results of a randomizedtrial comparing neoadjuvant chemotherapy (cisplatin,epirubicin, bleomycin) plus radiotherapy vs.radiotherapy alone in stage IV(> or = N2, M0) undifferentiatednasopharyngeal carcinoma: a positive effect on progression-freesurvival. International Nasopharynx CancerStudy Group. VUMCA I trial. Int J Radiat Oncol Biol Phys35:463–469Siu LL, Czaykowski PM, Tannock IF (1998) Phase I-II study of theCAPABLE regimen for patients with poorly differentiatedcarcinoma of the nasopharynx. J Clin Oncol 16: 2514–2521Sriuranpong V, Mutirangura A, Gillespie JW, et al (2004) Globalgene expression profile of nasopharyngeal carcinoma bylaser capture microdissection and complementary DNAmicroarrays. Clin Cancer Res 10:4944–4958Stein ME, Ruff P, Weaving A, et al (1996) A phase II study ofcisplatin/ifosfamide in recurrent/metastatic undifferentiatednasopharyngeal carcinoma among young blacks insouthern Africa. Am J Clin Oncol 19:386–388Sung FL, Hui EP, Tao Q, et al (2007) Genome-wide expressionanalysis using microarray identified complex signalingpathways modulated by hypoxia in nasopharyngeal carcinoma.Cancer Lett 253:74–88Sung FL, Poon TC, Hui EP, et al (2005) Antitumor effect andenhancement of cytotoxic drug activity by cetuximab innasopharyngeal carcinoma cells. In Vivo 19:237–245Taamma A, Fandi A, Azli N, et al (1999) Phase II trial of chemotherapywith 5-fluorouracil, bleomycin, epirubicin, andcisplatin for patients with locally advanced, metastatic, orrecurrent undifferentiated carcinoma of the nasopharyngealtype. Cancer 86:1101–1108Tan EH, Khoo KS, Wee J, et al (1999) Phase II trial of a paclitaxeland carboplatin combination in Asian patients with metastaticnasopharyngeal carcinoma. Ann Oncol 10: 235–237Tao Q, Chan AT (2007) Nasopharyngeal carcinoma: molecularpathogenesis and therapeutic developments. Expert RevMol Med 9:1–24Teo P, Tsao SY, Shiu W, et al (1989) A clinical study of 407 casesof nasopharyngeal carcinoma in Hong Kong. Int J RadiatOncol Biol Phys 17:515–530Wang CC, Liu TW, Lin CY, et al (2006) Phase II study of gemcitabineplus vinorelbine in the treatment of cisplatin-resistantnasopharyngeal carcinoma. Head Neck 28: 74–80Wang TL, Tan YO (1991) Cisplatin and 5-fluorouracil continuousinfusion for metastatic nasopharyngeal carcinoma.Ann Acad Med Singapore 20:601–603Wang X, Chow LS, Nicholls JM, et al (2002) Significance ofscheduling on the cytotoxicity of radiation and cisplatincombination treatment in nasopharyngeal carcinoma cells.Anticancer Drugs 13:957–964Wang X, Ling MT, Guan XY, et al (2004) Identification of anovel function of TWIST, a bHLH protein, in the developmentof acquired taxol resistance in human cancer cells.Oncogene 23:474–482Wang X, Wong H, Feng H, et al (2003) MAD2-induced sensitizationto vincristine is associated with mitotic arrest andRaf/Bcl-2 phosphorylation in nasopharyngeal carcinomacells. Oncogene 22:109–116